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Antiplatelets-30%. ConClusions: CHA2DS2-VASc showed better prediction than 
CHADS2 for stroke risk prediction. Dabigatran was observed to have better out-
come followed by VKA and Anti-platelets.
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objeCtives: To evaluate the management of Chronic Thromboembolic Pulmonary 
Hypertension (CTEPH) in a referral hospital by assessing clinical variables, patient-
reported outcomes and caregivers’ burden. Methods: An observational, retrospec-
tive study was conducted. All patients (aged > 18 years) attending the specialised 
unit on CTEPH at the 12 de Octubre Hospital (Spain), between January 2010 and 
November 2012, were offered to participate. Clinical variables were recorded at 
the clinical session for treatment decision (Pulmonary endarterectomy –PEA- if 
operability was confirmed or medication therapy –MT- if inoperable), and after 
one year. Outcomes considered: The New York Heart Association Functional Class 
(FC), 6-Minute Walking Distance, pulmonary arterial pressure, pulmonary vascular 
resistance and pro-brain natriuretic peptide. Participants completed the EQ-5D and 
caregivers’ fulfilled the Zarit Burden Interview. Differences between groups were 
studied (Chi-squared, Mann-Whitney U and ANCOVA). Results: A total of 64 CTEPH 
cases (57.8% males) were included. Mean (SD) age at diagnosis was 55.8 (14.9) and 
67.2% had an III-IV FC at diagnosis. At the moment of treatment prescription, dif-
ferences in clinical variables were not found (all p> 0.4) between PEA (n= 35-54.7%-) 
and MT groups (n= 29-45.3%-). After 12 months, 8 patients died (2 in PEA group and 
6 in MT). Among survivors, FC was significantly better in PEA group (93.9% improved 
at least one level). Regarding EQ-5D, patients undergoing PEA showed significant 
higher utilities (0.83-0.17- vs. 0.53-0.31-p= 0.007) and VAS values (80.22-14.24- vs. 
49.47-20.68-p< 0.001). Furthermore, mean VAS values in PEA group were comparable 
to general population (adjusted by sex and age). Finally, formal care was needed 
by just 4.8% of patients in PEA versus 33.3% in MT. Reported caregivers’ burden 
were relatively low in both groups (p= 0.87). ConClusions: The positive outcomes 
obtained, especially in those patients undergoing PEA, suggest the experienced 
management of CTEPH by this referral hospital and highlights the importance of 
detecting candidates for PEA.
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objeCtives: Few studies have assessed the real-life impact of secondary prevention 
drugs on all-cause mortality post-myocardial infarction (MI), especially in countries 
with low incidence of MI. The objective of this interim analysis after 3.5-year of follow-
up was to assess the real-life all-cause mortality impact of drugs reimbursed for 
MI secondary prevention in France: acetylsalicylic acid (ASA), anti-platelet agents 
(APA), beta-blockers (ß-), angiotensin converting enzyme inhibitors (ACEI), statins, and 
omega-3 supplementation (Om3). Methods: Cohort study of patients with recent 
(≤ 3 months) acute MI included by hospital and non-hospital cardiologists, with 6-year 
follow-up. Vital status was obtained from the National death registry, and failing that 
by patient/relatives/physicians investigation. Drug exposure was defined using both 
physician and patient reports at inclusion. Cox proportional hazard model was used 
to estimate for each drug, mortality hazard ratio (HR) of exposed versus non exposed 
patients, adjusted for gender, age, cardiovascular risk factors, other MI prevention 
drugs, and propensity score to be exposed at inclusion. Results: Between May 2006 
and June 2009, 596 physicians included 5538 patients: mean age 62.1 years, 77.6% male, 
9.6% current smokers, 14.5% diabetic, 44.6% hypercholesterolemic, 43.6% hyperten-
sive, 8.2% with LVEF < 40%. At inclusion, 97.5% were exposed to ASA, 91.0% to APA, 
89.7% to ß-, 71.1% to ACEI, 92.0% to statins, and 15.7% to Om3. The 3.5-year mortality 
was 7.8% (95%CI [7.1%-8.5%]) with an incidence rate of 23.2 per 1000 patient-years. 
Adjusted HR were: 0.98 [0.60-1.61] for ASA, 0.86 [0.60-1.24] for APA, 0.84 [0.63-1.11] 
for ß-, 0.80 [0.61-1.03] for ACEI, 0.67 [0.45-1.00] for statins, and 0.82 [0.58-1.16] for 
Om3. ConClusions: The 3.5 year interim all-cause real-life death reduction point 
estimates were close to those of large randomized controlled trials, except for ASA, 
for which almost all patients were exposed. The study’s statistical power will be suf-
ficient to confirm or not these trends at the final 6-year analysis.
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objeCtives: In 2012, the NHS Health and Social Care Information Centre (HSCIC), 
with support from NICE, reported on the eligible population for ezetimibe as a 
second-line lipid-lowering therapy (LLT) in England. Several populations were 
omitted from this analysis, including some very high-risk Type 2 Diabetes Mellitus 
(T2DM) patients with CVD. We re-evaluated the eligible population for ezetimibe 
indicated for treatment intensification in a retrospective analysis. Methods: 
Patients with ≥ 1 total cholesterol (TC) measure in each year of interest were iden-
objeCtives: To critically appraise the published network meta-analyses (NMAs) 
evaluating the efficacy or safety of the new oral anticogulants (NOACs) dabigatran, 
rivaroxaban and apixaban for the prevention of stroke in patients with non-valvular 
atrial fibrillation (AF). Methods: A systematic literature review was performed to 
identify the relevant NMAs using MEDLINE®, EMBASE®, Cochrane Library, Database 
of Abstracts of Reviews of Effects, and Health Technology Assessment. The synthesis 
studies were evaluated using the ‘Questionnaire to assess the relevance and cred-
ibility of the NMA’. Results: Eleven NMAs evaluating NOACs among adults with 
non-valvular AF were identified. Most NMAs included three large phase III RCTs, 
comparing NOACs to adjusted-dose warfarin (RE-LY, ROCKET-AF, ARISTOTLE). The 
main differences identified related to potential treatment effect modifiers regard-
ing the mean time spent in therapeutic range (TTR) in the warfarin arm, the risk of 
stroke or systemic embolism across the trials (mean CHADS2 score: Cardiac failure, 
Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke, 2 two points for stroke) or 
primary versus secondary prevention, and type of populations used in the analysis. 
Kansal et al. appropriately adjusted the ROCKET-AF TTR to match the RE-LY popula-
tion based on individual patient data. Meta-regressions are not expected to mini-
mize confounding bias given limited data, whereas subgroup analyses had some 
impact on the point estimates for the treatment comparisons. ConClusions: 
Results of the synthesis studies were generally comparable and suggested the 
NOACs had similar efficacy, although some differences were identified depending 
on the outcome. The extent to which the differences in the distribution of TTR, 
CHADS2 or primary versus secondary prevention biased the results remains unclear.
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objeCtives: To examine recommended target levels of low-density lipoprotein 
cholesterol (LDL-C) for hyperlipidaemia patients at high risk (i.e., with two or more 
risk factors or coronary heart disease or its risk equivalents) for cardiovascular dis-
ease (CVD); to determine the proportions of patients who do not achieve targeted 
LDL-C levels in real-world setting studies. Methods: A targeted literature review 
identified guidelines and real-world studies that analysed hyperlipidaemia patients 
who were not at goal (as defined by study). MEDLINE, Embase, the Cochrane Library, 
and BIOSIS databases were searched. Guideline publications were searched from 
2008; observational studies were searched from January 2005 to December 2013. 
There were no language or geographical restrictions. Results: 17 guidelines and 
70 observational studies were included in the review. While country-specific guide-
line recommendations vary slightly, the commonly used European Atherosclerosis 
Society and European Society of Cardiology (EAS/ESC) guidelines recommend a 
LDL-C target of < 2.5 mmol/L for patients with high CVD risk. Most studies reported 
that between 61.8% and 95.4% of high-risk patients did not reach this target. 3 
studies from North America reported lower proportions, between 18.9% and 42.3%. 
The EAS/ESC guidelines recommend a LDL-C target of < 1.8 mmol/L for patients 
with very high CVD risk. Studies reported that 68.1% to 96.0% of patients do not 
achieve this goal. ConClusions: Patients in higher cardiovascular-risk categories 
tend to have more stringent LDL-C target levels, which may contribute to failure to 
achieve target levels. This suggests several unmet needs: large numbers of patients 
who fail to achieve LDL-C targets, reducing the patients’ risk for CVD, and conse-
quently reduce the occurrence of cardiovascular events. Based on recently published 
American College of Cardiology and American Heart Association guidelines, which 
do not recommend a treatment target LDL-C level, further research is needed to 
re-evaluate the unmet need in hyperlipidaemia patients.
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objeCtives: Stroke Risk Stratification in AF patients of can be done using 
CHADS2 (Congestive heart failure, Hypertension, Age ≥ 75, DM, prior Stroke/TIA 
[2 points]); or CHA2DS2VASc2 (Congestive heart failure/left ventricular ejection 
fraction ≤ 35%, Hypertension, Age ≥ 75 [2 points], DM, prior Stroke/TIA/thrombo-
embolism [2 points], Vascular disease, Age 65–74, Sex- female). Treatment options 
for Prevention of stroke includes Anti-coagulants (Vitamin K Antagonist-Warfarin, 
Acenocoumarol; and Newer Oral Anticoagulant- Dabigatran) and anti-platelets 
(Aspirin and Clopidogrel). The objective of this study was to assess better tool 
for Stroke Risk Stratification; CHADS2 vs CHA2DS2VASc2 and to observe utiliza-
tion pattern of antithrombotics with stroke as the outcome. Methods: Elderly 
patients (Age> 65yrs) with Non-Valvular Atrial Fibrillation admitted in the hos-
pital within span of 2yrs (2012-13) were selected excluding patients with comor-
bidities like Atrial flutter, DVT, PFO, Endocarditis and/or ARF (after approval of 
ethical committee). Total of 160 patients were segregated based on stroke risk 
and percentage of patients experiencing thromboembolic event in each group 
was observed and CHADS2 and CHA2DS2-VASc were compared. The efficacy of 
antithrombotics in prevention of thromboembolic event in patients with AF was 
studied. Results: For stroke risk stratification, CHA2DS2-VASc was observed to 
be a better tool than CHADS2 to predict ‘truly low risk’, ‘moderate risk’ and ‘high 
risk’ patients. A shift of AF patients from ‘low-moderate risk’ by CHADS2 to ‘high 
risk’ by CHA2DS2VASc was noticed, 95% of patients required anticoagulation (either 
VKA or NOACs) as per CHA2DS2VASc, whereas, only 60% required OACs as per 
CHADS2. Most patients who experienced CVA belonged to ‘No antithrombotics 
prescribed’ group (25%). Dabigatran showed no incidence of CVA outcome, followed 
by VKA-, (Warfarin-28% and Acenocoumarol-18%) and least efficacy was seen by 
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objeCtives: To estimate the cumulative incidence and hospital cost for venous and 
pulmonary thromboembolic events in a real world setting in France. Methods: We 
conducted a retrospective analysis of the EGB database, a 1/97th random sample of 
the whole National health insurance database records linked to hospitalizations. 
All patients hospitalized in 2010 and 2011 with a diagnosis of deep vein thrombo-
sis (DVT) or pulmonary embolism (PE) were included. Inpatients were identified 
through principal diagnosis of hospitalization stay. Outpatients with a DVT were 
identified by 1) an echo Doppler exam, 2) preceded or followed by a low molecular 
weight heparin or fondaparinux delivery (+/-7 days), and 3) a subsequent Vitamin K 
antagonists delivery (0 to 7 days). Incidences and annual hospital cost of DVT and PE 
were estimated and extrapolated to the overall French population, and cumulative 
proportions of recurrences were calculated. Results: For 2011, the estimated crude 
incidences were 141/100,000 (91,650 patients) for DVT, and 79.4/100,000 for PE (51,610 
patients in France). Mean age of patients was 67.0+/-17.2 years for PE and 64.1+/-17.7 
years for DVT. A majority of patients were females (57% in both groups). After index 
event (PE/DVT), the cumulative proportions of venous thromboembolic recurrences 
were 2.6% at 1 month, 3.7% at 3 months, 5.1% at 6 months and 6.7% at 12 months. 
The cumulative proportions of death after a PE and a DVT first event were 0.2% at 1 
month, 1.1% at 3 months, 2.6% at 6 months and 6.2% at 12 months. Annual hospital 
cost of venous and pulmonary thromboembolic events was estimated at 712 million 
€ (362 million € for DVT and 350 million € for PE). ConClusions: In 2011, around 
143,000 patients suffered from venous and pulmonary thromboembolic events in 
France. Hospitalized events accounted for an important burden in France.
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COgnitiVe funCtiOn and nOn-adherenCe tO antihyPertensiVe 
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objeCtives: Non-adherence to blood pressure medications is common, present 
in 30-50% of patients, and known to be associated with an increased risk for major 
cardiovascular events and increased health care costs. Prior research suggests 
that impaired cognitive function is associated with medication non-adherence. 
Our aim was to determine if easily administered measures of cognitive function 
can be used to identify hypertensive patients at increased risk of medication non-
adherence. Methods: A convenience sample of 101 primary care patients (n= 101) 
with uncontrolled hypertension was enrolled from two hospital-based clinics in 
ethnically diverse communities of New York City. Patients with overt dementia 
as noted by their primary care doctors were ineligible. Subjects completed three 
brief cognitive tests (≤ 5 minutes to complete each one): Trail Making Test-A, Trail 
Making Test-B, and the Symbol Digit Modalities Test. The primary outcome was 
adherence based on percentage of doses taken as prescribed, measured by a 4-com-
partment electronic pillbox (MedSignals). Multivariable logistic regression was used 
to determine if impaired cognitive function was associated with poor adherence 
after adjusting for age, gender, ethnicity, education, and total blood pressure medi-
cations. Results: Patients who were classified as impaired when screened by 
Trail Making Test-B had a three-fold (OR= 2.91,95% CI, 1.02-8.35) increased likeli-
hood of non-adherence compared with those who were not impaired, adjusting 
for age, education, gender, ethnicity, and number of BP medications (p= . 05). Trail 
Making Test-A and Symbol Digit Modalities Test were non-significant predictors of 
adherence in both adjusted and unadjusted analyses. ConClusions: Trail Making 
Test-B, a measure of executive function, may be a useful screening tool to identify 
patients without overt dementia who are at risk for non-adherence to anti-hyper-
tensive medications. The findings from this study may provide an opportunity to 
identify a tailored approach to medication adherence interventions.
PCV28
retrOsPeCtiVe analysis On hOsPitalizatiOn and health Care COsts, 
aCCOrding tO seruM uriC aCid leVels in Patients frOM a saMPle Of 
italian lOCal health units
Degli Esposti L.1, Saragoni S.1, Buda S.1, Desideri G.2, Borghi C.3
1CliCon Srl, Ravenna, Italy, 2L’Aquila University, L’Aquila, Italy, 3Policlinico S. Orsola, University of 
Bologna, Bologna, Italy
objeCtives: Hyperuricemia is an independent risk factor for gouty arthropathy, 
renal disease, atherosclerosis and cardiovascular diseases (CVD). The objective of 
this study was to explore the relationship between serum uric acid (SUA) levels and 
hospitalization events and assess health care costs. Methods: A retrospective 
analysis using a large administrative database and a clinical registry containing 
laboratory results was performed. Subjects, aged ≥ 18, were assigned to one of 
the 4 groups based upon the first SUA measurement between October 1, 2010 and 
September 30, 2011: ≤ 6 mg/dl [good-control], > 6 mg/dl and ≤ 7 mg/dl [fair-control], 
> 7 mg/dl and ≤ 8 mg/dl [poor-control], > 8 mg/dl [very-poor-control]. We calculated 
incidence rates to estimate the risk of hyperuricemia-related and CVD hospitaliza-
tions occurred until December, 2012. A Poisson regression model was used to assess 
the relationship between the number of CVD hospitalizations and SUA level. Total 
annual costs included all the pharmacological treatments and the direct costs due 
to hospitalizations and outpatient services. Results: Of 52,822 patients included, 
SUA level was ≤ 6 mg/dl -good-control- for 33,638 (63.7%) patients and > 6 mg/dl 
–suboptimal-control- for 19,184 patients (36,3%), of whom 60,7% with fair-control, 
25,8% poor-control and 13,5% very-poor-control. Compared with good-control group, 
suboptimal-control patients showed an increased risk of hyperuricemia-related hos-
pitalizations (unadjusted rate was 1,02 vs 0,43 per 1000 person-years, p< 0.001) and 
of CVD hospitalizations (unadjusted rate 5,09 vs 3,17 per 100 person-years, p< 0.001; 
adjusted incidence rate ratio 1.22, p< 0.001). Over one year, the mean total cost was: 
€ 2,077.43 in good-control patients; € 2,079.87 in fair-control patients; € 2,296.39 in 
poor-control patients; € 3,295.41 in very-poor-control patients. ConClusions: The 
36,3% of the patients in this study sample were at sub-optimal SUA control (> 6mg/dl). 
This analysis indicates that higher hyperuricemia-related and CVD hospitaliza-
tions as well as total health care costs resulted associated with higher SUA levels.
tified from the Clinical Practice Research Datalink (CPRD). From this cohort, three 
groups of patients were identified and counted for 2010, 2011 & 2012: Group 1 – 
very high-risk T2DM patients with CVD, TC ≥ 4.0 to < 5.0mmol/l and low-density 
lipoprotein cholesterol ≥ 2.0mmol/l despite statin treatment; Group 2 – untreated 
patients, with a TC ≥ 5.0mmol/l who were not prescribed any LLT after ceasing statin 
therapy; Group 3 – patients prescribed atorvastatin, rosuvastatin and/or ezetimibe 
with TC < 5.0mmol/l who previously had TC ≥ 5.0mmol/l. Numbers were extrapolated 
to the population in England. Results: Of the general population in England in 
2012, 8, 200, 699 (15.4%) patients had a TC test recorded, with similar proportions 
in 2010 & 2011 (15.4% and 15.3% respectively). Among the three groups defined in 
this analysis, a total of 305, 261 patients eligible for ezetimibe were not included 
in the 2012 estimates by HSCIC. This represents an 80.0% increase of the original 
estimate of 381, 797 patients using the original HSCIC methodology, corresponding 
to 33, 753, 141, 619, and 129, 889 patients in Groups 1, 2 and 3, respectively. Hence 
a year-on-year increase in the estimated eligible population were observed com-
pared to the original HSCIC estimate; 64.8% increase in 2010 and 75.7% increase in 
2011. ConClusions: A significant and increasing number of high-risk patients 
eligible for ezetimibe were missed in the HSCIC estimates during 2010-2012.
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objeCtives: describe the prevalence of venous thromboembolism (VTE), pul-
monary embolism (PE) and deep vein thrombosis (DVT) without PE among all 
hospitalized patients and the percentages of those occurring during the hospital 
stays. Methods: Statistics are issued from the national PMSI MCO databases which 
are encoded using the CIM10. The codes used for VTE are I801 to I809 for DVT and 
codes I260, I269 for PE... Any stay with a the ICD-10 codes selected regardless of the 
Principal Diagnosis of Medical Unit Summaries and whatever its position (Principal, 
Related or Associated Diagnosis) was considered as a hospital-occurred thrombo-
sis unless it was the Principal Diagnosis of the first Medical Unit Summary of the 
stay. To eliminate outpatient consultations or in day care, stays of < 48 hours were 
excluded. The term of hospital-occurred is preferred to hospital-acquired VTE sug-
gesting a nosocomial origin which can be the case or not. Results: The results bear 
on the 18 683 603 hospital stays in 2010-2011. Out of 100 hospital stays involving VTE, 
for 40.3% VTE was the cause of hospitalization whereas 59.7% can be considered 
to have occurred during hospital-stay. These distributions are of 25.6% and 74.4% 
for DVT respectively 53.8% and 46.2% for PE. The age of patients varies little with 
whether VTE, DVT, and PE were hospital-occurred or not and are similar in men 
and women. The percentage of mortalities of these VTE is high and reaches 6.58% 
and the mortality from VTE, DVT, and PE is multiplied by a factor of 3 to 4 (p< . 0001) 
when hospital-occurred. ConClusions: The high proportion of hospital-occurred 
VTE is an alarming situation that should question the quality of prevention and/or 
its effectiveness. VTE prevention policies must be strengthened in hospitals for the 
sake of patients and health care savings alike.
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in a eurOPean POPulatiOn
Hamilton M.1, Gupta S.2, Goren A.3, Auziere S.4, Claflin A.B.5, Reboul R.4, Phatak H.1
1Bristol-Myers Squibb Company, Princeton, NJ, USA, 2Kantar Health, Princeton, NJ, USA, 3Kantar 
Health, New York, NY, USA, 4Kantar Health, Montrouge, France, 5Pfizer, Inc., New York, NY, USA
objeCtives: This study estimated venous thromboembolism (VTE) recurrence 
and associated risk factors in a European population, given limited data in this 
region. Methods: This retrospective cohort study included data from physicians 
(376 general practitioners and 307 specialists) in France, Spain, Italy, and Germany, 
who completed case report forms (2,184 patient records) for the next 3-4 patients 
seen in consultation for any reason who had an initial VTE event 3 to 24 months 
prior (i.e., patients surviving 90 days since initial VTE). All Anderson & Spencer 
individual risk factors (plus gender, bleeding, and initial VTE type, but excluding 
previous VTE and bed rest > 3 days) were entered into a Cox proportional hazard 
model accounting for censored data and predicting VTE recurrence. Backward step-
wise regression was used to select a reduced final model. Results: Patients’ mean 
age was 61.3 years (SD= 14.3) and 47.4% were female. Of 2,184 patients, 379 devel-
oped recurrent VTE over 1,298 person-years of follow-up. The final model included: 
age= 40+ (91.6%) vs. 18-39 years, varicose veins (26.4%), history of heart failure (5.9%), 
congestive respiratory failure (1.3%), arthroscopic knee surgery (2.2%), central 
venous line (0.9%), chemotherapy (6.1%), and orthopedic (3.1%) surgery. Significant, 
independent predictors of recurrence were: varicose veins (hazard ratio [HR]: 1.4; 
95% confidence interval [CI] 1.1-1.8), central venous line (HR: 3.2; CI 1.5-6.8), con-
gestive respiratory failure (HR: 2.4; CI 1.2-4.6), and heart failure (HR: 1.5; CI 1.1-2.2). 
Other factors, including age= 40+, knee surgery, chemotherapy, orthopedic surgery, 
and type of VTE (e.g., deep vein thrombosis vs. pulmonary embolism) did not exhibit 
significant associations with recurrence of VTE. ConClusions: VTE recurrence is 
high in this European population and associated with several independent risk fac-
tors. Targeted anticoagulant treatment post-initial VTE plus longer term prevention 
of recurrence are needed, including attention to risk factors that help differentiate 
patients more likely to experience recurrence.
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